ABLBio partners with GSK to develop CNS treatments using Grabody-B, potentially receiving up to £2.075B in milestone payments and royalties. Earlier deal with Sanofi is unlocking milestone payments.
What is covered in the Full Insight:
Introduction to ABL Bio and its recent licensing deal with GSK
Details and implications of the GSK agreement
Partnerships and progress with Sanofi and Compass Therapeutics
Ongoing clinical trial developments and pipeline advancements
Financial outlook and strategic positioning of ABL Bio
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.